Founded in 2004, ERYTECH Pharma develops innovative cancer therapies that work by starving tumours. Its first product, which is in phase III development, provides a therapeutic solution to frail patients with acute leukaemia.
ERYTECH proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.
The company has a production unit located in Lyons with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
ERYTECH Pharma reports revenues and cash balance for the fourth quarter of 2014 and provides an update on upcoming milestones
ERYTECH today announced the launch of a sponsored American Depository Receipt (ADR) Level 1 listing in the United States in order to support the expansion of the Company’s US investor base.
ERYTECH today announced that Pierre-Olivier Goineau will be leaving the company to pursue other interests.
ERYTECH reports additional positive Phase III results from the pivotal study with ERY-ASP/GRASPA® in Acute Lymphoblastic Leukemia
PARTNERING – ERYTECH Pharma participates in BIO Europe Spring 2015 which takes place in Paris, France from March 9 to 11, 2015
FINANCE – ERYTECH Pharma attends 3rd ANNUAL Sachs Cancer Bio Partnering & Investment Forum on February 23rd, 2015, New York City, NY, USA
SCIENTIFIC CONGRESS – ERYTECH Pharma attends Acute Leukemia XV from February 22 to 25, 2015 in Munich, Germany
FINANCE – ERYTECH Pharma participates on February 9-10, 2015 to BIO CEO INVESTOR Conference taking place in New York City, NY, USA